Sutro Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Sutro Biopharma has a total shareholder equity of $149.6M and total debt of $4.1M, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are $470.7M and $321.1M respectively.
Key information
2.7%
Debt to equity ratio
US$4.06m
Debt
Interest coverage ratio | n/a |
Cash | US$375.62m |
Equity | US$149.65m |
Total liabilities | US$321.09m |
Total assets | US$470.74m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: S09's short term assets ($421.5M) exceed its short term liabilities ($93.7M).
Long Term Liabilities: S09's short term assets ($421.5M) exceed its long term liabilities ($227.3M).
Debt to Equity History and Analysis
Debt Level: S09 has more cash than its total debt.
Reducing Debt: S09's debt to equity ratio has reduced from 11.2% to 2.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: S09 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: S09 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 20.6% each year.